Lion's mane

Lion's Mane (Hericium erinaceus): A Comprehensive Reference

1. Identity and Botanical Description

Taxonomic Classification and Nomenclature

Hericium erinaceus, commonly known as lion's mane mushroom, belongs to the tooth fungus family Hericiaceae. It is also known as Yamabushitake in Japan, belongs to the order Russulales, and is found throughout the northern hemisphere in Europe, Asia, and North America. Both the Latin genus name Hericium and the species name erinaceus mean 'hedgehog' in Latin. It is known in Japan as yamabushitake (Kanji: 山伏茸) in reference to the yamabushi or mountain ascetics of the syncretistic religion known as Shugendo; while in Chinese, it is known as hóutóugū (simplified Chinese: 猴头菇) meaning "monkey-head mushroom".

Other common names include hedgehog fungus, monkey head, bearded tooth, satyr's beard, and pom pom. Within the scientific literature, numerous synonyms have been applied to the species, all referring to the same fungal taxon. It was not until the 18th century that the mushroom was documented scientifically. Two mycologists took care of it: the first was the Frenchman J. B. F. Bulliard, who gave it the name Hydnum erinaceus; its current name was given by Ch. H. Persoon in 1797.

Morphology and Natural Distribution

The fungus derives its common name from its remarkable appearance, featuring cascading white spines that can reach 1–5 centimeters in length, creating a distinctive mane-like texture that resembles flowing hair. The mushroom grows as a single, globular to semi-spherical fruiting body ranging from 5–40 centimeters in diameter. The mature state of the fruiting body is easily discernible, with its basidiosome consisting of long branchless dangling spines that change in color from white to yellow and eventually, with aging, to brown.

Lion's mane mushroom typically grows on the trunks of dead hardwood trees. Native to North America and Eurasia, the mushrooms are common during late summer and autumn on hardwoods, particularly American beech and maple. It is typically considered saprophytic, as it mostly feeds on dead trees, but can also be found on living trees, usually in association with a wound.

Common Forms and Preparations

Lion's mane is commercially available in several distinct forms, each with different bioactive profiles. The distinction between fruiting body and mycelial extracts is significant due to the differing profiles of bioactive compounds. Fruiting bodies are rich in hericenones, which have been shown to enhance cognitive function and mood. In contrast, mycelia contain higher concentrations of erinacines, known for their neurotrophic effects.

Within the EU and UK, mycelial extracts or preparations of lion's mane mycelia are not allowed to be consumed within food products or nutritional supplements; however, fruiting body extracts are permitted. The use of solvents such as ethanol, methanol, or water significantly impacts bioactive yield and consumer acceptance. While water extraction aligns with preferences for natural and safe products, ethanol extraction is more favored in the extraction of terpenoids including hericenones.

Available commercial forms include dried whole mushroom powder, water or dual-extract powders, capsules, tablets, tinctures (liquid extracts), and culinary preparations (fresh or dried mushroom). The levels of hericenones and erinacines vary depending on the cultivation substrate and the fungal developmental stage. For instance, hericenones extracted from the fruiting body can be present at concentrations ranging from less than 20 to 500 µg/g of dry weight, whereas erinacines, found in the mycelium, can reach concentrations of approximately 150 µg/g.

2. Traditional and Historical Use

East Asian Medical Traditions

The genus Hericium, mushrooms belonging to the Hericiaceae family, has been used for both food and traditional medicine for over 2,000 years in East Asian countries such as China, India, Japan, and Korea. Notably, H. erinaceus has a long history of use in traditional Chinese medicine (TCM) in Asia, but was first described in North America.

In traditional Chinese medicine, it has been utilized as a tonic to strengthen digestion, enhance vitality, and alleviate stomach discomfort. Known as houtougu or "monkey head mushroom," it was prescribed to fortify the spleen, nourish the gut, and address conditions such as chronic gastritis and gastric ulcers by promoting the flow of qi and balancing internal energies. The fruiting body of Houtougu has been used as a traditional Chinese medicine for the treatment of dyspepsia and gastric ulcers, documented 1,000 years ago.

In Japanese kampo medicine, it is referred to as yamabushitake and employed historically to support gastrointestinal health, including the treatment of stomach ulcers, while also aiding vitality and nervous system function to combat weakness and insomnia. In Japan, it is traditionally used for its neuroprotective properties on the central nervous system.

H. erinaceus was used for centuries in traditional Chinese medicine generally as a tonic to relieve stress, anxiety, and depression. In Korea, it is primarily used for culinary purposes as an edible mushroom.

Traditional Preparations

In traditional Chinese contexts, it has been part of the materia medica, referenced in historical texts for various applications, often prepared as a tea or in soups. Buddhist monks in Japan (Yamabushi, hence the name Yamabushitake) were known to incorporate it, potentially valuing its unique properties within their practices. The mushroom was also consumed as a food ingredient throughout East Asia, where it is valued for its culinary qualities in addition to its medicinal applications.

3. Key Constituents and Active Compounds

Overview of Chemical Composition

The chemical composition of H. erinaceus includes polysaccharides, terpenoids (hericenones and erinacines), and phenolic compounds, which exhibit potent antioxidant effects by scavenging reactive oxygen species (ROS) and inducing endogenous antioxidant enzymes. Chemical analyses demonstrate multiple constituents including unique hericenones, erinacine terpenoids, beta-polysaccharides, and phenolic acids, as well as lectins, proteins, and fatty acids.

Hericenones

Hericenones are found in the fruiting body and appear to enhance or potentiate neurotrophin-activated signaling pathways. Multiple congeners have been characterized. Since the 1990s, several in vitro studies have been conducted, demonstrating the stimulatory effects on the synthesis of nerve growth factor (NGF) by hericenones (C, D, E, H) extracted from H. erinaceus. Research in PC12 cells demonstrated that hericenone E was able to stimulate NGF secretion which was two-fold higher than that of the positive control. The neuritogenesis process was partially blocked by the tyrosine kinase receptor (Trk) inhibitor K252a, suggesting that the neuritogenic effect was not solely due to NGF. Hericenone E also increased the phosphorylation of extracellular-signal regulated kinases (ERKs) and protein kinase B (Akt), suggesting that hericenone E potentiated NGF-induced neuritogenesis in PC12 cells via the MEK/ERK and PI3K/Akt pathways.

Erinacines

Erinacines originate from the mycelium and potently induce the synthesis of neurotrophins, protein growth factors essential for neuronal survival and health. The structures of novel diterpenoids, erinacines A, B, and C, isolated from the cultured mycelia of Hericium erinaceum, showed potent stimulating activity of nerve growth factor (NGF) synthesis. Erinacines A, B, C, and E have been confirmed to stimulate NGF synthesis in human astrocytoma cells. Erinacines are cyathin diterpenoids extracted from the mycelium that can traverse the blood–brain barrier. The lipophilic character of erinacines is understood to underlie this property: erinacines, being lipophilic, exhibit better blood–brain barrier permeability compared to hydrophilic polysaccharides like β-glucans, which primarily exert effects through immune modulation rather than direct neuroprotection.

Polysaccharides (β-Glucans)

Polysaccharides, particularly β-glucans, are known for their immunomodulatory and neuroprotective effects. Lion's mane (Hericium erinaceus) is rich in beta 1–3, 1–6 glucans known to have immunomodulating and antitumor effects. Recent research has demonstrated that H. erinaceus polysaccharides (HEPs) exhibit a range of beneficial properties, including immunomodulatory, anti-tumor, anti-inflammatory, antioxidant, gastrointestinal health enhancement, gastric protection, neuroprotective, and antiviral effects.

Phenolic Compounds and Other Constituents

Phenolic compounds, including gallic acid, caffeic acid, and p-coumaric acid, are also present in H. erinaceus and contribute to its strong antioxidant capacity. Ergothioneine in H. erinaceus has been detected at levels between 0.34 and 1.30 mg/g, depending on cultivation conditions. The full complement of identified secondary metabolites is extensive; more than a thousand components have been identified in Hericium erinaceus extracts, some of which are unique to this species of mushroom.

Established Mechanisms of Action

Nerve growth factor (NGF) has potent biological activities, such as preventing neuronal death and promoting neurite outgrowth, and is essential to maintain and organize neurons functionally. It is assumed that functional deficiency of NGF is related to Alzheimer's disease and plays a part in the etiology of the disease process. NGFs are proteins and so are unable to cross the blood–brain barrier; they are also easily metabolized by peptidases. Small-molecule inducers of NGF synthesis — such as the erinacines — are therefore of pharmacological interest precisely because they can cross this barrier and stimulate endogenous NGF production. Preclinical evidence substantiates the ability of these compounds to enhance neurotrophin levels, particularly NGF and brain-derived neurotrophic factor (BDNF), and to activate their cognate Trk receptors.

Additionally, H. erinaceus induces the synthesis of NGF, inhibits β-amyloid (Aβ) cytotoxicity, and protects nerve cells from death caused by oxidative stress or endoplasmic reticulum stress. It shows promising potential as a neuroprotective agent capable of stimulating nerve growth factor release, regulating inflammatory processes, reducing oxidative stress, and safeguarding nerve cells from apoptosis.

4. Scientific Evidence by Area of Use

4.1 Cognitive Function and Mild Cognitive Impairment

Evidence strength: Preliminary to moderate (small human RCTs, consistent but limited by sample size and duration)

The most frequently cited human trial in this area is by Mori et al. (2009). Mori et al. (2009) reported that in 30 patients with mild cognitive impairment (MCI), 16-week treatment with 3,000 mg (four 250 mg tablets three times per day) of 96% lion's mane supplement derived from the fruiting body improved cognition on the Revised Hasegawa Dementia Scale (HDS-R). In this double-blind, parallel-group, placebo-controlled trial of 30 subjects aged 50–80 with mild cognitive impairment, 16 weeks of Hericium erinaceus supplementation produced significantly higher cognitive function scores at weeks 8, 12, and 16 compared to placebo. This improvement was observed throughout the trial period at assessment during weeks 8, 12, and 16, but not at the follow-up observation 4 weeks after treatment cessation, suggesting that prolonged supplementation may be necessary to exert beneficial effects.

A second notable clinical study investigated erinacine A-enriched mycelial extract. Similar reductions in cognitive decline were observed in patients diagnosed with mild Alzheimer's disease following 49-week supplementation with erinacine A-enriched H. erinaceus (three 350 mg capsules daily, each containing 5 mg/g erinacine A). This trial observed improvements on the Mini-Mental State Examination at week 49, alongside significant treatment-related differences in Instrumental Activities of Daily Living scores, suggesting better cognition and a lower level of dependence following supplementation.

In healthy younger adults, a 2023 randomized double-blind placebo-controlled pilot study tested acute and chronic effects. This trial investigated the acute (60 min post-dose) and chronic (28-day intervention) effects of 1.8 g Hericium erinaceus in 41 healthy adults aged 18–45 years. Analysis revealed that following a single dose, participants performed more quickly on the Stroop task (p = 0.005) at 60 minutes post-dose. A trend towards reduced subjective stress was observed following 28-day supplementation (p = 0.051). The findings tentatively suggest that Hericium erinaceus may improve speed of performance and reduce subjective stress in healthy, young adults; however, null and limited negative findings were also observed.

Cognitive effects with lion's mane have been mixed based on small and short-duration clinical trials. Clinical trials testing lion's mane interventions have included small numbers of participants with short durations of treatment. Well-designed larger and longer clinical trials are needed. Despite promising results from preclinical trials, limited research has investigated the potential cognition-enhancing effects of H. erinaceus in humans, with much of this work focusing on cognitively compromised demographics.

4.2 Mood: Depression and Anxiety

Evidence strength: Preliminary (small human studies, positive signals but methodological limitations)

H. erinaceus has been evaluated for its effects on mood disorders, with clinical evidence suggesting its potential to alleviate symptoms of anxiety and depression. Additional trials suggest a mood-enhancing effect of H. erinaceus, with lowered depression and anxiety scores observed in menopausal women following 4 weeks of supplementation with H. erinaceus-containing cookies (four consumed each day, each with 0.5 g of powdered fruiting body). Similar reductions in depression, anxiety, and sleep disorder scores were observed in overweight and obese adults following 8-week 550 mg H. erinaceus (80% bulk mycelia, 20% fruiting body extract) supplementation in combination with a low-calorie diet. These mood improvements were associated with a change in peripheral pro-BDNF.

HE enhanced pro-BDNF and BDNF production, promoted hippocampal neurogenesis, improved behavior, and reduced symptoms of depression, anxiety, binge eating, and sleep disorders across the studies included in a 2025 systematic review. While promising, these results highlight the need for larger-scale studies with longer follow-up periods to establish definitive clinical efficacy.

4.3 Neurodegenerative Disease (Alzheimer's Disease)

Evidence strength: Predominantly preclinical; one small pilot human RCT

Much of the mechanistic data in this area is from animal models. Treatment of mice with erinacine A or S also reduced amyloid plaques, astro- and microgliosis, increased levels of IDE (but not NGF), increased neurogenesis, and improved cognition. The mycelium polysaccharide-enriched aqueous extract of lion's mane also improved cognition and increased the levels of acetylcholine and choline acetyltransferase (ChAT) in a D-galactose-induced model of Alzheimer's disease. Finally, feeding mice a diet of lion's mane improved cognition in a model of intracerebroventricular (ICV) injection of Aβ.

In humans, the pilot double-blind placebo-controlled study of erinacine A-enriched mycelia in early Alzheimer's disease (described above under cognitive function) represents the primary controlled human evidence at this time. Mori et al. found that cessation of HE supplementation decreased scores for the cognitive function assessment significantly, suggesting that cognitive decline and AD pathological processes rebounded to pre-HE states, and that continuous use of HE presents a challenge when the intended participants for treatment suffer from AD memory impairment. Most of these effects have been demonstrated in cell culture or in animal models but have not been found in humans in replicated, large-scale trials.

4.4 Gastrointestinal Health

Evidence strength: Preliminary; animal and in vitro data predominate, with limited human evidence

Several studies have highlighted the therapeutic potential of H. erinaceus for gastrointestinal disorders such as gastritis and inflammatory bowel diseases. In addition, some components of this mushroom appear to possess strong antineoplastic capabilities against gastric and colorectal cancer. Polysaccharides from H. erinaceus reduce proinflammatory cytokines and enhance anti-inflammatory responses in vitro and in vivo.

Clinical trials have also examined the role of H. erinaceus in gastrointestinal health. A study in patients with gastritis found that supplementation with H. erinaceus significantly reduced inflammation-related symptoms, improved mucosal healing, and modulated gut microbiota composition. These findings suggest potential applications in managing gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), where chronic inflammation plays a central role.

HE has demonstrated the potential to inhibit the growth of Helicobacter pylori, a bacterium known for causing chronic gastritis and peptic ulcers. HE extracts have been observed to protect against gastric mucosal damage and edema, and to provide cytoprotection against ethanol-induced gastric ulcers in animal models.

HE also increased gut microbiota diversity and the abundance of SCFA-producing bacteria, thereby reducing inflammation and protecting gut health. These findings across multiple study types are generally preclinical or from small human studies, and replication in large clinical trials is lacking.

4.5 Immune Function

Evidence strength: Preclinical and mechanistic; limited direct human trials

Laboratory and animal studies suggest lion's mane polysaccharides (particularly beta-glucans from the fruiting body) have antioxidant, anti-inflammatory, and immunomodulatory effects. An important nuance was identified in human blood cell research: mycelium extract reduced certain markers of inflammation, while fruiting body extract increased a key marker of inflammation. This suggests that the immune effects may differ — or even be opposing — depending on which part of the fungus is used. This observation underscores why part-of-mushroom distinction matters and why results from mycelium and fruiting body studies cannot be freely extrapolated to each other.

4.6 Antimicrobial Activity

Evidence strength: Preliminary in vitro only

H. erinaceus shows promising antimicrobial activity against bacterial and fungal pathogens, with potential applications in combating antibiotic-resistant infections. These findings are based primarily on in vitro studies; no human clinical trials have been conducted specifically to evaluate antimicrobial efficacy in this context.

4.7 Antioxidant Activity

Evidence strength: Well-characterized mechanistically; human clinical data lacking

Polysaccharides, terpenoids (hericenones and erinacines), and phenolic compounds in H. erinaceus exhibit potent antioxidant effects by scavenging reactive oxygen species (ROS) and inducing endogenous antioxidant enzymes. Phenolic compounds, including gallic acid, caffeic acid, and p-coumaric acid, contribute to its strong antioxidant capacity. The clinical relevance of these in vitro antioxidant findings remains to be confirmed in human studies.

4.8 Cancer-Related Research

Evidence strength: In vitro and animal data only; no human clinical trials

Studies have indicated that HE mushroom extracts can inhibit the proliferation of various cancer cells, including liver cancer (HepG2 and Huh-7), colon cancer (HT-29), gastric cancer (NCI-87 cells), breast cancer (MCF-7), cervical cancer (HeLa), human acute promyelocytic leukemia (HL-60), and lung fibroblast cells (HEL-299). No human clinical trials have specifically evaluated lion's mane for cancer prevention or treatment.

5. Body Systems and Health Areas of Association

• Nervous system: Positive effects of H. erinaceus have been observed in research contexts related to cognitive disorders, Alzheimer's disease, ischemic strokes, Parkinson's disease, and age-related hearing impairment. These are predominantly preclinical; human trials are small and preliminary.
• Mood and mental health: Promising results have been obtained in the treatment of depressive disorders. Human evidence exists but remains limited in scale and duration.
• Gastrointestinal system: H. erinaceus exhibits significant gastroprotective effects, especially against gastric ulcers and inflammatory bowel diseases, based primarily on animal and limited human data.
• Immune system: Beta-glucan polysaccharides are the primary bioactives implicated in immune modulation, with evidence from cell culture and animal studies.
• Metabolic health: As a traditional medicine, lion's mane was purported to have multiple potentially beneficial activities including antioxidant, antidiabetic, antilipidemic, antihypertensive, antineoplastic, and immunomodulatory activities, as well as hepatoprotective, neuroprotective, and cardiovascular protective properties. Most of these effects have been demonstrated in cell culture or in animal models but have not been found in humans.

6. Dosage Forms and Dosages Reported in Studies

Dosages and formulations vary considerably across published studies. The following figures are drawn directly from cited sources:

• The Mori et al. (2009) MCI trial used 3,000 mg per day of fruiting body-derived lion's mane supplement (four 250 mg tablets, three times per day) for 16 weeks.
• The early Alzheimer's pilot study used three 350 mg capsules daily, each containing 5 mg/g erinacine A (erinacine A-enriched H. erinaceus mycelia), for 49 weeks.
• The 2023 Docherty et al. pilot study in healthy young adults used 1.8 g Hericium erinaceus (single dose, acute) and for 28 days (chronic) in 41 healthy adults aged 18–45 years.
• The menopausal women study used four cookies per day, each containing 0.5 g of powdered fruiting body (totaling 2 g/day), for 4 weeks.
• The study in overweight and obese adults used 550 mg H. erinaceus (80% bulk mycelia, 20% fruiting body extract) for 8 weeks.

Further research is needed to elucidate the pharmacokinetics of H. erinaceus compounds in humans, including their metabolism, half-life, and optimal dosing strategies for neuroprotection. No universally accepted therapeutic dose has been established by any regulatory or pharmacopoeial body.

7. Safety Considerations and Interactions

General Safety Profile

A 2025 systematic review (covering 26 studies published between 2000 and 2024) concluded that HE is effective in neuroprotection, enhancing cognitive function, preventing and alleviating cancer, promoting gut health, and improving symptoms of anxiety and depression. Although commonly unreported, potential side effects of HE include stomach discomfort, headache, and allergic reactions.

A double-blind randomized controlled trial of 30 people with mild cognitive impairment reported that lion's mane mushroom treatment for 16 weeks resulted in no adverse effects on laboratory tests. One patient did withdraw from the study due to stomach discomfort.

Hepatotoxicity

H. erinaceus has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury. A case report described a patient on chemotherapy taking a multi-mushroom supplement that included both lion's mane and Agaricus blazei; the supplement contained two mushroom species and the authors attributed the liver changes primarily to Agaricus blazei, not lion's mane. The patient was on chemotherapy, introducing potential drug-supplement interactions. Liver function improved after discontinuing the supplement.

Allergic Reactions

True IgE-mediated allergy to lion's mane has been documented in case reports, including at least one case of anaphylaxis reported in the peer-reviewed literature (Kobernick, 2022, Annals of Allergy, Asthma & Immunology). Although lion's mane is an edible mushroom, there is little published information on whether lion's mane supplements are safe for long-term use.

Regulatory Status and Part-Specific Restrictions

Within the EU and UK, mycelial extracts or preparations of lion's mane mycelia are not permitted to be consumed within food products or nutritional supplements; however, fruiting body extracts are permitted. Consumers and practitioners should be aware that not all commercial products disclose which portion of the fungus was used or how extracts have been standardized.

Drug Interactions

No formal pharmacokinetic drug-interaction studies in humans have been published specifically for lion's mane. The theoretical basis for interactions is related to its immunomodulatory (β-glucan) and neurotrophin-stimulating mechanisms. Individuals on immunosuppressive therapies, anticoagulants, or chemotherapeutic agents should be aware that supplement-drug interactions are a recognized consideration. Despite promising findings, clinical validation remains limited, and the safety data available in humans apply primarily to healthy adults over short to medium time horizons.

Mycelium-on-Grain Products: Quality Concern

A documented quality concern in the commercial supplement market relates to products labeled as lion's mane that are derived from mycelium cultivated on grain substrates. Not all lion's mane extracts contain equal proportions of purported bioactives. Variability arises from factors such as the source of raw material, extraction methods, and extract constituents. Residual grain substrate in such products can represent a significant portion of the measured weight, diluting the true fungal content and potentially altering the beta-glucan and terpenoid profile.

References

• Lion's Mane Mushroom (Hericium erinaceus): A Neuroprotective Fungus with Antioxidant, Anti-Inflammatory, and Antimicrobial Potential — A Narrative Review. PMC / Nutrients, 2025.
• Lion's Mane — LiverTox®, NCBI Bookshelf (NIH National Library of Medicine), 2024.
• Neurotrophic and Neuroprotective Effects of Hericium erinaceus. PMC / International Journal of Molecular Sciences, 2023.
• The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study. PMC / Nutrients, 2023.
• Benefits, Side Effects, and Uses of Hericium erinaceus as a Supplement: A Systematic Review. PMC, 2025.
• Acute Effects of a Standardised Extract of Hericium erinaceus on Cognition and Mood in Healthy Younger Adults: A Double-Blind Randomised Placebo-Controlled Study. PMC / Frontiers in Nutrition, 2025.
• Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Frontiers in Aging Neuroscience, 2020.
• Hericenones and Erinacines: Stimulators of Nerve Growth Factor (NGF) Biosynthesis in Hericium erinaceus. Mycology, 2010.
• Nerve Growth Factor-Inducing Activity of Hericium erinaceus in 1321N1 Human Astrocytoma Cells. PubMed / Biological and Pharmaceutical Bulletin, 2008.
• Hericium erinaceus Cultivated Under Tropical Conditions: Isolation of Hericenones and Demonstration of NGF-Mediated Neurite Outgrowth in PC12 Cells via MEK/ERK and PI3K-Akt Signaling Pathways. PubMed, 2014.
• Benefits, Side Effects, and Uses of Hericium erinaceus as a Supplement: A Systematic Review. PubMed, 2025.
• Bioactive Substances in Hericium erinaceus and Their Biological Properties: A Review. ScienceDirect / Journal of Future Foods, 2024.
• Effect of Erinacine A-Enriched Hericium erinaceus Supplementation on Cognition: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. ScienceDirect, 2024.
• The Ethnopharmacology, Phytochemistry and Pharmacology of the Genus Hericium. ScienceDirect / Journal of Ethnopharmacology, 2024.
• Bioactive Polysaccharides from Hericium erinaceus: Extraction, Structure, Bioactivities, and Applications. PMC, 2025.
• Lion's Mane & Your Brain. Cognitive Vitality, Alzheimer's Drug Discovery Foundation.
• Beyond Neurotrophins: A Proposed Neurotrophic-Epigenetic Axis Mediated by Non-Coding RNA Networks for Hericium erinaceus Bioactives — A Hypothesis-Driven Review. PubMed, 2026.
• Hericium erinaceus. Wikipedia (for nomenclature and taxonomy cross-reference).
• Hericium erinaceus: A Possible Future Therapeutic Treatment for the Prevention and Delayed Progression of Alzheimer's Disease? Nutrition Research Reviews, Cambridge University Press, 2025.